Cofoe Medical Technology Co., Ltd.
可孚醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1187)

ANNOUNCEMENT
CHANGE IN PURPOSE OF REPURCHASED A SHARES AND CANCELLATION AS WELL AS REDUCTION OF REGISTERED CAPITAL AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Cofoe Medical Technology Co., Ltd. (the "**Company**") convened the 8th meeting of the third session of the board of directors on August 28, 2026, at which the Resolution on Change in Purpose of Repurchased A Shares and Cancellation as well as Reduction of Registered Capital and Amendments to the Articles of Association was considered and approved, pursuant to which, the Company intends to change the purpose of the 397,000 A shares out of the total number of A shares repurchased under its 2022 share repurchase plan from "for implementation of employee stock ownership plan or as equity incentive" to "for cancellation and reduction of registered capital", and proposes to the general meeting of the Company to authorize the management or its authorized representative(s) to go through the subsequent procedures relating to share cancellation as well as change in industrial and commercial registration and filing of the amended articles of association of the Company. The aforesaid matter is subject to consideration at the general meeting of the Company. Details are hereby announced as follows:

I. INFORMATION ON THE 2022 SHARE REPURCHASE PLAN

(I) Share Repurchase Plan and its Implementation

At the 25th meeting of the first session of the board of directors and the 16th meeting of the first session of the supervisory committee of the Company held on December 29, 2022, the Resolution on Plan Regarding Repurchase of the Shares of the Company was considered and approved, pursuant to which, the Company proposed to repurchase its Renminbi-denominated A ordinary shares with its own funds by way of centralized auction trading, for the purpose of implementing employee stock ownership plan or as equity incentive. The total amount of funds allocated to share repurchase shall not be lower than RMB100 million (inclusive) or higher than RMB200 million (inclusive), the repurchase price shall not exceed RMB60.00/share (inclusive), and the valid period for share repurchase shall be 12 months from the date of consideration and approval of the share repurchase plan by the board of directors of the Company. For details, please refer to the Announcement on Share Repurchase Plan (Ann No. 2022-070) and Report on Repurchase (Ann No. 2023-002) disclosed by the Company on the website of the Shenzhen Stock Exchange at www.szse.cn on December 30, 2022 and January 4, 2023, respectively.

As of December 28, 2023, the Company had completed the share repurchase plan, and a total of 4,202,369 shares were repurchased by the Company through its special securities accounts designated for repurchase by way of centralized auction trading, accounting for 2.01% of the then total share capital of the Company, at the highest and lowest trading prices of RMB39.77/share and RMB36.00/share, respectively, with an aggregate consideration of RMB156,323,240.30 (exclusive of transaction expenses). For details, please refer to the Announcement on Results of Share Repurchase and Change in Share Capital (Ann No.2023-083) disclosed by the Company on the website of the Shenzhen Stock Exchange at www.szse.cn on December 29, 2023.

(II) Utilization of the Repurchased Shares

On October 31, 2025, the Company vested a total of 1,821,000 Class II restricted shares to the 301 participants who satisfied relevant vesting conditions upon maturity of the first vesting period under the initial grant of the 2024 restricted stock incentive plan.

As of the date of this announcement, 2,381,369 shares remained outstanding in the Company's special securities accounts designated for implementation of its 2022 repurchase plan.

II. REASONS FOR AND EXPLANATION OF CHANGE IN PURPOSE OF REPURCHASED A SHARES AND CANCELLATION

According to relevant requirements under the Company Law of the People's Republic of China (《中華人民共和國公司法》), the Share Repurchase Rules for Listed Companies (《上市公司股份回購規則》), the Self-Regulatory Guideline for Companies Listed on the Shenzhen Stock Exchange No. 9 – Share Repurchase (《深圳證券交易所上市公司自律監管指引第9號—回購股份》) and the Company's share repurchase plan, any outstanding portion out of the shares repurchased by the Company for the purpose of equity incentive scheme or employee stock ownership plan, if not transferred pursuant to the disclosed purposes, shall be cancelled in accordance with law. The Company intends to change the purpose of the 397,000 A shares out of the total number of A shares repurchased under its 2022 share repurchase plan from "for implementation of employee stock ownership plan or as equity incentive" to "for cancellation and reduction of registered capital", and cancel such number of repurchased shares. The board of directors of the Company proposes to the general meeting to authorize the management or its authorized representative(s) to go through the subsequent procedures relating to share cancellation as well as change in industrial and commercial registration and filing of the amended articles of association of the Company.

III. CHANGE IN SHARE CAPITAL STRUCTURE OF THE COMPANY FOLLOWING CANCELLATION OF REPURCHASED A SHARES

As of the date of this announcement, the Company had a total of 235,897,000 shares. Following completion of cancellation of the repurchased shares, the total share capital of the Company will be reduced by 397,000 shares, and its registered capital will be accordingly reduced by RMB397,000. Details regarding the change in the Company's share capital are set out below:

	Before change		Number of shares proposed to be cancelled (share)	After change	
Nature of shares	*Number (share)*	*Proportion (%)*		*Number (share)*	*Proportion (%)*
A shares	208,897,000	88.55	397,000	208,500,000	88.54
Tradable shares subject to trading moratorium (A shares)	14,905,730	6.32	–	14,905,730	6.33
Tradable shares not subject to trading moratorium (A shares)	193,991,270	82.24	397,000	193,594,270	82.21
Of which: shares in special securities accounts designated for repurchase	8,767,681	3.72	397,000	8,370,681	3.55
H shares	27,000,000	11.45	–	27,000,000	11.46
Total number of shares	235,897,000	100.00	397,000	235,500,000	100.00

Notes:

1. Actual change in the Company's share capital is subject to the shareholding structure statement issued by the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited following cancellation of the repurchased shares;

2. In the above table, the difference in the last decimal place between the total and the direct sum of addends, if any, is a result of rounding.

IV. DETAILS ON REDUCTION IN THE REGISTERED CAPITAL AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Following completion of cancellation of the 397,000 repurchased shares, the total share capital and registered capital of the Company will be reduced from 235,897,000 shares to 235,500,000 shares, and from RMB235,897,000 to RMB235,500,000, respectively. The Company will, in compliance with the requirements of the Guidelines for the Articles of Association of Listed Companies (《上市公司章程指引》), Self-Regulatory Guideline for Companies Listed on the Shenzhen Stock Exchange No. 2 – Standardized Operation of Companies Listed on ChiNext (《深圳證券交易所上市公司自律監管指引第2號－創業板上市公司規範運作》) and relevant laws, regulations and regulatory documents, make corresponding amendments to relevant articles of the Articles of Association of the Company as detailed below:

Existing article	Amended article
Article 6 The registered capital of the Company is RMB235,897,000.	**Article 6** The registered capital of the Company is RMB235,500,000.
Article 17 After the completion of the initial public offering of H Shares, the total number of the shares of the Company is 235,897,000, all of which are ordinary shares, including 208,897,000 A ordinary shares and 27,000,000 H ordinary shares.	**Article 17** The total number of the shares of the Company is 235,500,000, all of which are ordinary shares, including 208,500,000 A ordinary shares and 27,000,000 H ordinary shares.

Save and except for the articles subject to amendments as set out above, other articles of the Articles of Association of the Company shall remain unchanged.

The change in registered capital and amendments to the Articles of Association are subject to consideration and approval by the general meeting of the Company.

V. IMPACT OF THE CHANGE IN PURPOSE OF REPURCHASED A SHARES AND CANCELLATION ON THE COMPANY

The change in purpose of repurchased shares and cancellation is in line with relevant requirements under the Share Repurchase Rules for Listed Companies (《上市公司股份回購規則》) and Self-Regulatory Guideline for Companies Listed on the Shenzhen Stock Exchange No. 9 – Share Repurchase (《深圳證券交易所上市公司自律監管指引第9號－回購股份》). It is resolved by the Company in light of its actual condition, and will not have any material impact on the operation, profitability, finance, research and development, and prospects of the Company, nor will it result in a change in the control of the Company or its listing status, render its shareholding structure not in conformity with listing conditions, or infringe upon the interests of the Company and its shareholders, especially the minority shareholders.

VI. SUBSEQUENT ARRANGEMENTS FOLLOWING THE CHANGE IN PURPOSE OF REPURCHASED A SHARES

According to relevant laws, regulations and the Articles of Association of the Company, the change in purpose of repurchased shares and cancellation as well as reduction of registered capital and amendments to the Articles of Association of the Company is subject to consideration at the general meeting of the Company, and an application for cancellation is required to be filed to the Shenzhen Stock Exchange and the Shenzhen Branch of China Securities Depository and Clearing Corporation Limited in accordance with relevant requirements. The board of directors of the Company proposes to the general meeting of the Company to authorize the management or its authorized representative(s) to go through the subsequent procedures relating to share cancellation as well as change in industrial and commercial registration and filing of the amended articles of association of the Company. The specific changes shall be subject to approval and registration by market supervision authorities.

The board of directors of the Company will keep informed of subsequent developments, and perform information disclosure obligations in a timely manner in strict accordance with laws, regulations and regulatory documents.

By Order of the Board
Cofoe Medical Technology Co., Ltd.
ZHANG Min
Executive Director and Chairman of the Board

Hong Kong, August 28, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Mr. ZHANG Min, Mr. ZHANG Zhiming, Mr. XUE Xiaoqiao and Mr. HE Bangjie as executive directors; and (ii) Mr. NING Huabo, Ms. SHEN Nan and Mr. ZHOU Rong as independent non-executive directors.